12:29 PM EDT, 10/08/2025 (MT Newswires) -- Philip Morris International ( PM ) said Wednesday that experts from the company met with the US Food and Drug Administration's advisory committee as part of its request to continue marketing versions of its IQOS heated tobacco products in the US as modified risk tobacco products.

The evidence presented by the company on Tuesday to the Tobacco Products Scientific Advisory Committee backs the health regulator's original conclusions to authorize the IQOS system as a modified risk tobacco product, Philip Morris International US Chief Executive Stacey Kennedy said in a statement.

Kennedy also urged the FDA to set up a timely review process for smoke-free products, including IQOS Iluma, which has been pending regulatory review for about two years.

Price: 154.18, Change: -0.37, Percent Change: -0.24